Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06239064

Early Genetic Identification of Obesity

TITLE: Whole genetic approach in Early Genetic Identification of Obesity (WEGIO)

DESIGN: Multicenter epidemiological study

STUDY POPULATION: Participants at risk for a syndromic or a monogenic genetic obesity, incl. participants clinically diagnosed with Bardet-Biedl-Syndrome (BBS)

NUMBER OF PARTICIPANTS: 1000 for initial genetic sequencing and app. 40 for the follow-up documentation

COORDINATING INVESTIGATOR: Prof. Dr. Arndt Rolfs

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

About this study

TITLE: Whole genetic approach in Early Genetic Identification of Obesity (WEGIO)

DESIGN: Multicenter epidemiological study

STUDY POPULATION: Participants at risk for a syndromic or a monogenic genetic obesity, incl. participants clinically diagnosed with Bardet-Biedl-Syndrome (BBS)

NUMBER OF PARTICIPANTS: 1000 for initial genetic sequencing and app. 40 for the follow-up documentation

COORDINATING INVESTIGATOR: Prof. Dr. Arndt Rolfs

PARTICIPATING COUNTRY: Germany

TREATMENT: Not applicable

PRIMARY OBJECTIVE: To investigate the prevalence of BBS in an at-risk population

SECONDARY OBJECTIVES:

  • To explore genotype-phenotype correlation
  • To assess genotypes distribution in Germany and compare to other countries
  • To identify new genes/variants
  • To investigate clinical characteristics in individuals diagnosed with BBS

DURATION OF RECRUITMENT: 32 months - total

24 months the recruitment of 1000 subjects

27 months follow up visits

32 months close out of sites

Inclusion criteria

  • Informed consent is obtained from the participant/parent/legal guardian
  • The participant is 2 years of age or older

For a participant between 2 and 18 years of age:

  • The participant has and had a body weight more than 97th percentile before the age of 6
  • The participant has one or more of the following symptoms:

rod/cone dystrophy, renal abnormalities, ataxia, syndactyly, polydactyly, brachydactyly, hyperphagia, cognitive impairment, speech delay, hypogonadism

For a participant who is 18 years of age or older:

  • The participant has BMI ≥ 30 kg/m2
  • The participant had a body weight more than 97th percentile before the age of 6 years
  • The participant has rod/cone dystrophy
  • The participant is 2 or more years of age, is clinically diagnosed with Bardet-Biedl-Syndrome (BBS) or is a sibling of an individual diagnosed with BBS via the WEGIO study

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent is obtained from the participant/parent/legal guardian
  • The participant is 2 years of age or older

For a participant between 2 and 18 years of age:

  • The participant has and had a body weight more than 97th percentile before the age of 6
  • The participant has one or more of the following symptoms:

rod/cone dystrophy, renal abnormalities, ataxia, syndactyly, polydactyly, brachydactyly, hyperphagia, cognitive impairment, speech delay, hypogonadism

For a participant who is 18 years of age or older:

  • The participant has BMI ≥ 30 kg/m2
  • The participant had a body weight more than 97th percentile before the age of 6 years
  • The participant has rod/cone dystrophy
  • The participant is 2 or more years of age, is clinically diagnosed with Bardet-Biedl-Syndrome (BBS) or is a sibling of an individual diagnosed with BBS via the WEGIO study

Exclusion criteria

  • Not fulfilling the inclusion criteria

Treatment and study plan

Genetic testing via blood collection

Diagnostic Test

blood collection

Primary outcomes

  1. BBS prevalence

    Time frame: 2 years

    To investigate the prevalence of BBS in patients suspected to a genetic obesity

Secondary outcomes

  1. Phenotypic and genetic characterization

    Time frame: 2 years

    To understand the genotype-phenotype correlation; to assess genotypes distribution in Germany and compare to other countries; to identify new genes/variants; to investigate clinical characteristics in individuals diagnosed with BBS

Sponsors and collaborators

Lead sponsor

Rolfs Consulting und Verwaltungs-GmbH (RCV)

Network

Collaborators

  • Rhythm Pharmaceuticals, Inc.

Registry information

Official study title

Whole Genetic Approach in Early Genetic Identification of Obesity (WEGIO)

Acronym: WEGIO

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Feb 2, 2024
Registry last updated
Sep 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.